I-Corps: Commercialization study of Marangoni Mediated Lyopreservation

I-Corps：马兰戈尼介导冷冻保存的商业化研究

• 批准号: 1643225
• 负责人: Nilay Chakraborty
• 金额: $ 5万
• 依托单位: Regents of the University of Michigan - Ann Arbor
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2017-02-28
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1643225&HistoricalAwards=false
• 关键词: Corps; Commercialization; study; Marangoni; Mediated

The broader impact/commercial potential of this I-Corps project is to evaluate the market potential of a technology that can essentially store and transport molecules of biological and clinical significance without refrigeration. Currently, the lack of proper infrastructure of cold-chain logistics geographically limits distribution and storage of critical biomolecules. The development and commercial implementation of a technology that can enable room temperature stabilization of important biological molecules opens the door for highly sensitive diagnostic devices in the field and in developing regions. Furthermore, stabilization of biologics at room temperature can significantly reduce shipping and storage costs reducing the overall end-user pricing for the drugs. A business strategy based on successful implementation of such a technology can provide a strong case for delivering high quality healthcare anywhere.This I-Corps Project is based on a novel method for creating a highly uniform vitrified (glassy) coating to preserve and protect temperature sensitive biologics including cells and proteins. Formation of a uniformly vitrified environment surrounding the biomolecules in thin film format can arrest degradative chemical reactions and enable storage. The thin-film vitrification technique primarily depends on preferential desiccation of a substrate containing the biomolecules. The technique utilizes a carbohydrate- based formulation which facilitates rapid vitrification at desiccated state. Besides biomolecules, hepatocellular carcinoma (HepG2) cells vitrified at ambient temperatures using this process have been shown to successfully retain their viability following processing.

这个i-Corps项目的更广泛的影响/商业潜力是评估一种技术的市场潜力，这种技术基本上可以在不冷藏的情况下存储和运输具有生物和临床意义的分子。目前，冷链物流缺乏适当的基础设施，在地理上限制了关键生物分子的分配和储存。能够使重要生物分子在室温下稳定下来的技术的开发和商业实施，为现场和发展中地区的高灵敏度诊断设备打开了大门。此外，生物制剂在室温下的稳定性可以显著降低运输和储存成本，从而降低药物的总体最终用户价格。基于这种技术的成功实施的商业战略可以为在任何地方提供高质量的医疗保健提供强有力的案例。这个i-Corps项目基于一种新的方法，创建高度均匀的玻璃化(玻璃)涂层，以保存和保护温度敏感的生物，包括细胞和蛋白质。以薄膜形式在生物分子周围形成均匀的玻璃化环境可以阻止降解的化学反应并使存储成为可能。薄膜玻璃化技术主要依赖于含有生物分子的基质的优先干燥。这项技术利用了碳水化合物为基础的配方，便于在干燥状态下快速玻璃化。除了生物分子，使用这种方法在常温下玻璃化冷冻的肝细胞癌(HepG2)细胞被证明在处理后成功地保持了它们的活力。